中国HCV基因型分布的Meta分析*

doi:10.3969/j.issn.1672-5069.2021.05.022

摘要/Abstract

摘要： 目的分析中国不同地区、民族和感染途径人群丙型肝炎病毒(HCV)基因型的分布特点。方法通过检索万方数据库和NCBI数据库中有关中国HCV基因型分布的文献,按照地区、民族和感染途径进行数据分类,应用Meta分析研究HCV基因型的分布特点。结果在我国,HCV1型流行最广泛,北部地区主要为1型(52.7%～79.7%)和2型(13.9%～44.9%),东南部地区主要为1型(51.7%～79%),6型在香港(31.3%)、广东(23.1%)、福建(21.8%)、澳门(20.6%)地区分布较多,西南部地区主要为1型(19.7%～73.4%)和3型(13.4%～58.5%),西部地区主要为1型(53.6%～66.8%),也有较多的2型(15.8%～32.1%)和3型(12.8%～15.8%);朝鲜族2型比例(42.2%)显著高于汉族(22.4%,P<0.001)、维吾尔族(13.1%,P<0.001)和哈萨克族(18.5,P=0.004),维吾尔族3型比例(16.6%)显著高于汉族(9.4%,P<0.001);静脉吸毒人群感染HCV 3型比例(31.1%)显著高于血液感染相关人群(4.5%,P<0.001)、性传播感染人群(24.1%,P=0.003),静脉吸毒人群感染HCV6型比例(26.7%)显著高于血液感染相关人群(4.1%,P<0.001)和性传播感染人群(15.1%,P<0.001);在HCV/HIV混合感染者中3型和6型比例显著高于单纯HCV感染者(P<0.001)。结论在不同地区、民族和感染途径人群中HCV基因型分布存在显著性差异,了解这些差异并进行针对性的处理可能有助于防治研究。

关键词: 丙型肝炎, 病毒基因型, 分布, 流行

Abstract: Objective The aim of this study was to investigate the distribution of hepatitis C virus (HCV) genotypes among people in different regions, ethnic groups and transmission risk factors in China. Methods Papers on the studies of HCV genotypes in China were searched in Wanfang and NCBI database, and the data was classified by different regions, ethnic groups, and transmission risk factors. The data was analyzed by meta-analysis to observe the distribution of genotypes. Results In China, the HCV genotype 1 was the most prevalent, the HCV genotypes were mainly genotype 1 (52.7%-79.7%) and genotype 2 (13.9-44.9%) in the northern region, the HCV genotypes were mainly genotype 1 (51.7%-79%) in the southeast region, and the genotype 6 was widely distributed in Hong Kong (31.3%), Guangdong (23.1%), Fujian (21.8%) and Macau (20.6%); the HCV genotypes were mainly genotype 1 (19.7%-73.4%) and genotype 3 (13.4%-58.5%) in the southwest region; the main genotypes distributed in the western region were genotype 1 (53.6%-66.8%), genotype 2 (15.8%-32.1%) and genotype 3 (12.8%-15.8%); the proportion of genotype 2 in Korean nationality was (22.4%, P<0.001), in Uyghur(13.1%, P<0.001) and in Kazakh (18.5%, P<0.05), and the proportion of genotype 3 in Uyghur was 16.6%,significantly higher than 9.4% of the Han nationality 42.2%, significantly higher than that in Han (P<0.001); the proportion of genotype 3 in persons with intravenous drug use was 31.1%, significantly higher than with blood transmission infected (4.5%, P<0.001) or sexual transmission infected (24.1%, P<0.05), and the proportion of genotype 6 infection in intravenous drug users was 26.7% , significantly higher than by blood transmission infection (4.1%, P<0.001) or by sexual transmission infection (15.1%, P<0.001); the proportion of type 3 and type 6 in individuals with HCV/HIV mixed infection were higher than that in with HCV infection alone (all P<0.001). Conclusion There are differences in the distribution of HCV genotypes among individuals in different regions, in different ethnic groups and with different transmission routs.

Key words: Hepatitis C, Genotype, Distribution, Prevalence

何勇, 张振华, 刘忠萍, 伍宵, 孙秋林. 中国HCV基因型分布的Meta分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 693-696.

He Yong, Zhang Zhenhua, Liu Zhongping, et al. Meta-analysis on distribution of hepatitis C virus genotypes in China[J]. Journal of Practical Hepatology, 2021, 24(5): 693-696.

参考文献

[1]Williams R. Global challenges in liver disease. Hepatology,2006,44(3):521-526.
[2]Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology,2013,57(4):1333-1342.
[3]WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization,2018,https://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en/.
[4]中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2019年版).实用肝脏病杂志,2019,23(1):33-52.
[5]Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology,2005,42(4):962-973.
[6]Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology,2014,59(1):318-327.
[7]Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol,2017,2(3):161-176.
[8]Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology,2015,61(1):77-87.
[9]苏迎盈, 刘慧鑫, 汪宁. 中国丙型肝炎病毒基因型分布. 中华流行病学杂志,2013,34(1):80-84.
[10] Du G, Li X, Musa TH, et al. The nationwide distribution and trends of hepatitis C virus genotypes in mainland China. J Med Virol,2019,91(3):401-410.
[11] Rao H, Wei L, Lopez-Talavera JC, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol,2014,29(3):545-553.
[12] Probst A, Dang T, Bochud M, et al. Role of hepatitis C virus genotype 3 in liver fibrosis progression-a systematic review and meta-analysis. J Viral Hepat,2011,18(11):745-759.
[13] Lee MH, Yang HI, Lu SN, et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol,2010,28(30):4587-4593.
[14] Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol,2009,24(3):336-345.
[15] Fu Y, Qin W, Cao H, et al. HCV 6a prevalence in Guangdong province had the origin from Vietnam and recent dissemination to other regions of China:phylogeographic analyses. PLoS One,2012,7(1):e28006.
[16] Zhang Z, Yao Y, Wu W, et al. Hepatitis C virus genotype diversity among intravenous drug users in Yunnan province, southwestern China. PLoS One,2013,8(12):e82598.
[17] Zhang C, Wu N, Liu J, et al. HCV subtype characterization among injection drug users: implication for a crucial role of Zhenjiang in HCV transmission in China. PLoS One,2011,6(2):e16817.
[18] Liu J, Zhang C. Phylogeographic analyses reveal a crucial role of Xinjiang in HIV-1 CRF07_BC and HCV 3a transmissions in Asia. PLoS One,2011,6(8):e23347.
[19] Tao J, Liang J, Zhang H, et al. Themolecular epidemiological study of HCV subtypes among intravenous drug users and non-injection drug users in China. PLoS One,2015,10(10):e0140263.
[20] Ju W, Yang S, Feng S, et al. Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6. Virol J,2015,12:109.
[21] Lingala S, Ghany MG. Natural history of hepatitis C. Gastroenterol Clin North Am,2015,44(4):717-734.
[22] Wu N, Rao HY, Yang WB, et al. Impact of hepatitis C virus genotype 3 on liver disease progression in a Chinese national cohort. Chin Med J (Engl),2020,133(3):253-261.

中国HCV基因型分布的Meta分析^*

Meta-analysis on distribution of hepatitis C virus genotypes in China

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	姜浩, 张雯, 陈霞. 长效干扰素联合利巴韦林治疗慢性丙型肝炎患者疗效及其对静息能量消耗和营养状态的影响^*[J]. 实用肝脏病杂志, 2021, 24(6): 815-818.
[2]	黄飞虎, 薛建亚, 朱咏梅, 余姣, 王丽艳, 鲁琼. 应用索磷布韦/维帕他韦治疗门诊和住院筛查的丙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(6): 819-822.
[3]	贾坤, 苏建荣, 孙伟. 慢性丙型肝炎患者血清和外泌体LncRNA HEIH水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(6): 823-826.
[4]	束青华, 张楠楠, 葛勇胜. 不同HCV基因型感染的慢性丙型肝炎和肝硬化患者对重组人干扰素α-2a治疗应答的影响[J]. 实用肝脏病杂志, 2021, 24(6): 899-902.
[5]	韩宏艳, 潘娟, 蒋文平, 张敏. 3D方案治疗基因1b型低病毒载量慢性丙型肝炎患者应答疗效研究^*[J]. 实用肝脏病杂志, 2021, 24(5): 689-692.
[6]	安红杰, 徐金凤, 耿华, 葛志胜, 何文艳, 赵崇山, 高美丽, 陈俊, 周东方. FibroScan行肝脏硬度检测和APRI评估慢性丙型肝炎患者肝纤维化程度价值比较^*[J]. 实用肝脏病杂志, 2021, 24(4): 492-495.
[7]	王嘉妮, 刘湧, 周忻, 任传路, 缪惠锴. 慢性丙型肝炎患者血清microRNA-1273g-3p水平预测肝硬化价值分析^*[J]. 实用肝脏病杂志, 2021, 24(4): 496-499.
[8]	李拓键, 张超, 陈宗涛. 重庆市800名教职工健康体检脂肪肝检出情况分析^*[J]. 实用肝脏病杂志, 2021, 24(4): 512-515.
[9]	郝肖伟, 白娜, 郭小军, 陈永刚. 慢性丙型肝炎合并非酒精性脂肪性肝病患者血清A-FABP水平变化及其临床意义[J]. 实用肝脏病杂志, 2021, 24(3): 347-350.
[10]	白洁, 任艳, 梁晨, 汤珊, 刘念晨, 白丽, 刘霜, 郑素军, 段钟平. 1996～2020年北京佑安医院遗传代谢性肝病住院患者流行病学特征分析[J]. 实用肝脏病杂志, 2021, 24(2): 164-167.
[11]	樊秉栋, 张国华, 王君. 索磷布韦/维帕他韦联合利巴韦林治疗慢性丙型肝炎患者疗效临床研究[J]. 实用肝脏病杂志, 2021, 24(1): 31-34.
[12]	杨晓冬, 贾婷, 张秀灵, 高斯媛, 余向琼, 李冬玲, 喻明丽, 林潮双. 达诺瑞韦联合长效α-干扰素治疗基因3型慢性丙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2021, 24(1): 35-38.
[13]	崔璐瑶, 苑喜微, 刘领弟, 张莹, 赵文, 赵丹丹, 杨杨, 南月敏. 血浆GP73联合肝脏硬度检测诊断乙型和丙型肝炎患者肝纤维化临床价值分析^*[J]. 实用肝脏病杂志, 2020, 23(6): 809-812.
[14]	刁青, 段银环, 苗亮, 王守云. DAAs治疗丙型肝炎肝硬化患者疗效及安全性研究^*[J]. 实用肝脏病杂志, 2020, 23(6): 841-844.
[15]	周长雄, 于文虎, 金笛. 艾尔巴韦/格拉瑞韦治疗慢性丙型肝炎患者疗效初步观察[J]. 实用肝脏病杂志, 2020, 23(5): 646-649.